"Second Genome is intent on cracking the code of the gut microbiome, which plays a role in metabolic and autoimmune processes. 'There’s a large amount of bacterial diversity, but much of it is functionally conserved,' said Peter DiLaura, CEO. 'The link between the microbiome and disease is strongest in inflammatory and metabolic diseases, and in hospital-acquired infections.'
The company is developing microbiome modulators to promote the growth of beneficial bacteria. 'We’ve built a platform to look at microbial interactions and are conducting preclinical research on obesity and type 2 diabetes. Last year, we got blank stares when we discussed the gut microbiome. This year, we’re in back-to-back meetings,' he said. 'Second Genome has collaborations with Merck and Danisco, and an early-stage pipeline is emerging.'"
Small Firms Look Optimistically to Future - Genetic Engineering & Biotechnology News